Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Neven

Showing results (271-280 of 383) with videos related to

Pageof 39
Sort By:
Breast Cancer Research : BCR|June 13, 2025
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric studyKaren Van Baelen, Ha-Linh Nguyen, François Richard, et al.
Acta Clinica Belgica|July 12, 2017
Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumabTine Loyson, Thomas Van Cann, Patrick Schöffski, et al.
Science Translational Medicine|July 22, 2021
Toward predicting CYP2D6-mediated variable drug response from <i>CYP2D6</i> gene sequencing dataMaaike van der Lee, William G Allard, Rolf H A M Vossen, et al.
The Lancet. Oncology|December 5, 2024
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.
Breast (Edinburgh, Scotland)|April 29, 2014
Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph nodeAnneleen Reynders, Olivier Brouckaert, Ann Smeets, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98Giuseppe Viale, Meredith M Regan, Eugenio Maiorano, et al.
The Lancet. Oncology|April 1, 2021
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.
NPJ Genomic Medicine|April 28, 2022
Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancerAdriaan Vanderstichele, Pieter Busschaert, Chiara Landolfo, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2010
Breast cancer in pregnancy: recommendations of an international consensus meetingFrédéric Amant, Sarah Deckers, Kristel Van Calsteren, et al.
Gynecologic Oncology|September 2, 2018
The genetic landscape of 87 ovarian germ cell tumorsEls Van Nieuwenhuysen, Pieter Busschaert, Patrick Neven, et al.
Pageof 39

Showing results (271-280 of 383) with videos related to

Sort By:
Pageof 39
Breast Cancer Research : BCR|June 13, 2025
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric studyKaren Van Baelen, Ha-Linh Nguyen, François Richard, et al.
Acta Clinica Belgica|July 12, 2017
Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumabTine Loyson, Thomas Van Cann, Patrick Schöffski, et al.
Science Translational Medicine|July 22, 2021
Toward predicting CYP2D6-mediated variable drug response from <i>CYP2D6</i> gene sequencing dataMaaike van der Lee, William G Allard, Rolf H A M Vossen, et al.
The Lancet. Oncology|December 5, 2024
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.
Breast (Edinburgh, Scotland)|April 29, 2014
Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph nodeAnneleen Reynders, Olivier Brouckaert, Ann Smeets, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98Giuseppe Viale, Meredith M Regan, Eugenio Maiorano, et al.
The Lancet. Oncology|April 1, 2021
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.
NPJ Genomic Medicine|April 28, 2022
Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancerAdriaan Vanderstichele, Pieter Busschaert, Chiara Landolfo, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2010
Breast cancer in pregnancy: recommendations of an international consensus meetingFrédéric Amant, Sarah Deckers, Kristel Van Calsteren, et al.
Gynecologic Oncology|September 2, 2018
The genetic landscape of 87 ovarian germ cell tumorsEls Van Nieuwenhuysen, Pieter Busschaert, Patrick Neven, et al.
Pageof 39